News and Features

Global Philippines Fine Living

INVESTMENT STRATEGY

Economy Stocks Bonds Currencies

THE BASICS

Investment Tips Explainers Retirement

2024 Mid-Year Economi Briefing, economic growth in the Philippines

2024 Mid-Year Economic Briefing: Navigating the Easing Cycle

Investing with Love

Investing with Love: A Mother’s Guide to Putting Money to Work

retirement-ss-3

Investor Series: An Introduction to Estate Planning

September 1, 2023

View All Webinars

Candle stick and line charts on a black computer screen

Consensus Pricing

Consensus Pricing – November 21, 2024

Printing money on a roll

Economic Updates

The cycle continues: Fed to support the labor market

Makati City skyline

Economic Updates

Green light for BSP

View all Reports

Metrobank.com.ph Contact Us

Follow us on our platforms.

Login

Access Exclusive Content

Login to Wealth Manager

Economy 1 MIN READ

BRIEF-Shanghai Henlius Biotech Announces License Agreement With Getz Pharma For Rights Of Handayuan

February 23, 2022

By Reuters

Feb 23 (Reuters) – Shanghai Henlius Biotech Inc 2696.HK:

ANNOUNCES LICENSE AGREEMENT WITH GETZ PHARMA FOR RIGHTS OF HANDAYUAN
TO GRANT LICENSE TO GETZ PHARMA TO COMMERCIALISE ADALIMUMAB INJECTION IN PAKISTAN, PHILIPPINES, AMONG OTHER COUNTRIES

Further company coverage: 2696.HK

((Reuters.Briefs@thomsonreuters.com;))

This article originally appeared on reuters.com

Read More Articles About:

Worldwide News Philippine News Rates & Bonds Equities Economy Investment Tips Fine Living

Web Analytics